ROYCE & ASSOCIATES LP CPRX — CATALYST PHARMACEUTICALS INC

Ownership history in ROYCE & ASSOCIATES LP  ·  25 quarters on record

AI Ownership Summary

ROYCE & ASSOCIATES LP reported CATALYST PHARMACEUTICALS INC (CPRX) in 25 quarterly 13F filings from 2023 Q4 through 2025 Q4. Peak portfolio weight reached 0.45% in 2025 Q4. The latest visible filing shows CPRX at 0.45% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this CPRX ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was ROYCE & ASSOCIATES LP's position in CATALYST PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

CPRX was reported at 0.45% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.45% in 2025 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

CPRX stock page ROYCE & ASSOCIATES LP fund profile ROYCE & ASSOCIATES LP full holdings
How ROYCE & ASSOCIATES LP held CPRX — position size vs. price
% of Fund (quarterly)    CPRX price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 9 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 REDUCED 6.1% +6.1% ❌ 1,910,767 -124,198 -6.1% 0.45% $44.6M 2026-02-14 (Est.) $24.33
2025 Q3 ADDED — — — 2,034,965 +452,103 +28.6% 0.40% $40.1M 2025-11-12 $22.78
2025 Q2 REDUCED — — — 1,582,862 -15,498 -1.0% 0.35% $34.3M 2025-08-11 $19.68
2025 Q1 REDUCED 14.3% -10.5% ✅ 1,598,360 -265,991 -14.3% 0.42% $38.8M 2025-05-06 $23.06
2024 Q4 REDUCED 7.8% +16.2% ❌ 1,864,351 -156,754 -7.8% 0.36% $38.9M 2025-02-10 $22.76
2024 Q3 REDUCED 6.5% +6.0% ❌ 2,021,105 -140,917 -6.5% 0.37% $40.2M 2024-11-06 $22.71
2024 Q2 ADDED — — — 2,162,022 +78,009 +3.7% 0.31% $33.5M 2024-08-13 $19.59
2024 Q1 ADDED — — — 2,084,013 +340,939 +19.6% 0.30% $33.2M 2024-05-13 $16.22
2023 Q4 ADDED — — — 1,743,074 +131,372 +8.2% 0.27% $29.3M 2024-02-12 $13.64
16 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding CPRX

As of 2026 Q1 — sorted by position size

GABLES CAPITAL MANAGEMENT INC. 3Y 7Y 4.45% JW Asset Management, LLC 3Y 7Y 3.95% Advisors Preferred, LLC 3Y 7Y 1.39% Future Fund LLC 3Y 0.82% Zinnia Wealth Advisory, LLC 0.61% JUNCTURE WEALTH STRATEGIES, LLC 3Y 7Y 0.59% AlphaCentric Advisors LLC 3Y 0.58% Jackson Creek Investment Advisors LLC 3Y 0.56% Stanley-Laman Group, Ltd. 3Y 7Y 0.47% Linden Thomas Advisory Services, LLC 3Y 0.39%

FAQ About ROYCE & ASSOCIATES LP and CPRX

These are the practical questions this page is built to answer before you even open the full history table.

How long has ROYCE & ASSOCIATES LP reported owning CPRX?

ROYCE & ASSOCIATES LP reported CPRX across 9 quarterly 13F filings, from 2023 Q4 through 2025 Q4.

What was the largest reported CPRX position in ROYCE & ASSOCIATES LP's portfolio?

The largest reported portfolio weight for CPRX was 0.45% in 2025 Q4.

What is the latest reported CPRX position on this page?

The most recent filing on this page is 2025 Q4, when ROYCE & ASSOCIATES LP reported 1,910,767 shares, equal to 0.45% of portfolio, with an estimated market value of $44.6M.

What does the chart on this CPRX ownership page compare?

The chart compares ROYCE & ASSOCIATES LP's quarterly CPRX portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did ROYCE & ASSOCIATES LP time their CPRX position?

Based on 13F filing dates vs. subsequent CPRX price moves, ROYCE & ASSOCIATES LP correctly timed 11 out of 24 reported position changes (46%). The annualised alpha on CPRX relative to SPY over the holding period was +15.8%.

← Back to ROYCE & ASSOCIATES LP Holdings